MedTrace Logo

The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer

NCT06915714 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-04-08

No results posted yet for this study

Summary

Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024. The inclusion criteria were as follows: (1) patients with diagnosis of metastatic hormone-sensitive prostate cancer, confirmed by PSA levels, radiographic tests and pathological information; (2) patients who underwent FDG and PSMA PET/CT prior to the initiation of medical treatment. The exclusion criteria were as follows: (1) patients who received novel hormone therapy or a prostate biopsy prior to PET/CT; (2) patients with other malignancies; (3) patients received hormone therapy without NHT; (4) patients received chemotherapy or radiotherapy prior to or during novel hormone therapy; (5) absence of follow-up data at the hospital.

Conditions

  • Prostate Cancer Metastatic Disease
  • PET / CT

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Fangzheng Xiang · First affiliated hospital, Sun Yat-sen univeristy

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-02
Primary Completion
2025-02-20
Completion
2025-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06915714 on ClinicalTrials.gov